6 Amendments of Eleonora EVI related to 2017/2254(INI)
Amendment 108 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Stresses that the appropriate and prudent use of antimicrobials is essential to limiting the emergence of AMR in human healthcare, animal husbandry and aquaculture; stresses that there are considerable differences in the way Member States handle and address AMR; calls on the Commission to consider mandatory routine collection and submission of monitoring data at EU level, making them also available to the public, and to establish indictors to measure progress in the fight against AMR;
Amendment 217 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Is aware that the cost of rapid diagnostic tools (RDT) may exceed the price of antibiotics; calls on the Commission to propose incentives for the industry to develop effective and efficient testing methods and calls on health insurance carriers to cover the extra cost arising from the use of RDT, making sure that patients do not have to bear that cost, given the long-term benefits of preventing the unnecessary use of antimicrobials;
Amendment 233 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Calls on the Commission and the Member States to restrict or stop the sale of antibiotics by those doctors or veterinarians who prescribe them;
Amendment 244 #
Motion for a resolution
Paragraph 11 a (new)
Paragraph 11 a (new)
11a. Calls on the Member States to prohibit the sale of antibiotics without a doctor's or veterinarian's prescription;
Amendment 254 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. HighlightConsiders theat value of vaccinesccines whose efficacy and safety have been scientifically tested can play a major role in combating AMR; recommends integration of targets for life-long vaccination as a key element of national action plans on AMR;
Amendment 336 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Encourages the European Medicines Agency (EMA) to review all available information on the benefits and risks of older antimicrobial agents, including antibiotics in combination, and to consider whether any changes to their approved uses are required;